Mokari Atabak sold $2.8M of CORT
Mokari Atabak (Chief Financial Officer) sold 40,000 shares of CORCEPT THERAPEUTICS INC (CORT) at $70.00 ($2.80M total) on 2026-06-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The main tradable element is potential short-term sentiment impact from insider selling; however, the pre-arranged 10b5-1 plan generally lowers interpretive weight.
Market read
A routine 10b5-1 insider sale disclosure; likely low incremental fundamental impact.
What to watch
Form 4s often aggregate multiple scheduled trades; without context on prior/next tranche sizes, the incremental signal is weak.
Background
The article is an SEC EDGAR Form 4 insider transaction disclosure for Corcept Therapeutics, reporting an open-market sale by the CFO.
Ticker impact
Corcept Therapeutics CFO Mokari Atabak sold 40,000 shares in an open-market transaction disclosed via SEC Form 4 on June 1 under a 10b5-1 plan.
Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment/positioning.
The filing is an ownership-change disclosure (Form 4) with a stated pre-arranged 10b5-1 plan, which typically dampens interpretive value versus discretionary selling.
Market effects
Limited read-through to biotech/pharma sector fundamentals; this is company-specific insider activity.
No clear regional spillover expected from a single Form 4 transaction.
Minimal global relevance; disclosure is routine and not tied to operational or regulatory events.
Counterpoint
Because the sale is on a 10b5-1 plan, it may reflect routine liquidity needs rather than negative expectations; any dip could be overdone.
Key entities
- issuerCorcept Therapeutics Inc
Subject of the Form 4 insider transaction disclosure.
- insiderMokari Atabak
Chief Financial Officer who sold 40,000 shares.
